EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evolutionary rescue by aneuploidy in tumors exposed to anticancer drugs

Remus Stana, Uri Ben-David, Daniel B Weissman iD, Yoav Ram iD

GENETICS · 2025

DOI: 10.1093/genetics/iyaf098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift GENETICS, 2025. Verfasst von Remus Stana und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Zoology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel. Hauptthemen laut MEDLINE: Aneuploidy, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation, US-Israel Binational Science Foundation, Simons Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evolutionary rescue occurs when a population, facing a sudden environmental change that would otherwise lead to extinction, adapts through beneficial mutations, allowing it to recover and persist. A prime example of evolutionary rescue is the ability of cancer to survive exposure to treatment. One evolutionary mechanism by which a population of cancer cells can adapt to chemotherapy is aneuploidy. Aneuploid cancer cells can be more fit in an environment altered by anticancer drugs, in part because aneuploidy may disrupt the pathways targeted by the drugs. Indeed, aneuploidy is highly prevalent in tumors, and some anticancer drugs fight cancer by increasing chromosomal instability. Here, we model the impact of aneuploidy on the fate of a population of cancer cells. We use multitype branching processes to approximate the probability that a tumor survives drug treatment as a function of the initial tumor size, the rates at which aneuploidy and other beneficial mutations occur, and the growth rates of the drug-sensitive and drug-resistant cells. We also investigate the effect of the preexistent aneuploid cells on the probability of evolutionary rescue. Finally, we estimate the tumor’s mean recurrence time to revert to its initial size following treatment and evolutionary rescue. We propose that aneuploidy can play an essential role in the relapse of smaller secondary tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AneuploidyNeoplasmsAntineoplastic AgentsHumansMutationDrug Resistance, NeoplasmChromosomal InstabilityEvolution, MolecularBiological Evolution

Stichwörter der Autor:innen

adaptive evolutionaneuploidycancerchromosome instabilitydrug resistanceevolutionary model

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • School of Zoology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Department of Physics, Emory University, Atlanta, GA 30322, USA.

ORCID-Profile: Daniel B Weissman, Yoav Ram

Förderung

  • Israel Science Foundation
  • US-Israel Binational Science Foundation
  • Simons Foundation
  • Sloan Foundation
  • National Science Foundation
  • ERC
  • US–Israel Binational Science Foundation

Zitieren

APA

Stana, R., Ben-David, U., Weissman, D. B., & Ram, Y. (2025). Evolutionary rescue by aneuploidy in tumors exposed to anticancer drugs. GENETICS. https://doi.org/10.1093/genetics/iyaf098

Vancouver

Stana R, Ben-David U, Weissman DB, Ram Y. Evolutionary rescue by aneuploidy in tumors exposed to anticancer drugs. GENETICS. 2025. doi:10.1093/genetics/iyaf098

BibTeX
@article{Stana2025,
  author = {Stana, Remus and Ben-David, Uri and Weissman, Daniel B and Ram, Yoav},
  title = {Evolutionary rescue by aneuploidy in tumors exposed to anticancer drugs},
  journal = {GENETICS},
  year = {2025},
  doi = {10.1093/genetics/iyaf098}
}
Kostenlos starten →